188铼-羟基亚乙基二膦酸盐在人前列腺癌骨转移中的剂量测定

Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.

作者信息

Liepe Knut, Hliscs Reiner, Kropp Joachim, Runge Roswitha, Knapp Furn F, Franke Wolf-Gunter

机构信息

Department of Nuclear Medicine, University Hospital Dresden, Dresden, Germany.

出版信息

J Nucl Med. 2003 Jun;44(6):953-60.

PMID:12791825

Abstract

UNLABELLED

188Re-Hydroxyethylidene diphosphonate ((188)Re-HEDP) was used in previous studies for the palliative treatment of metastatic bone pain. However, the kinetic and radiation-absorbed doses have not been well documented. Therefore, the aim of this study was to gather dosimetric data for (188)Re-HEDP.

METHODS

Thirteen prostate cancer patients with skeletal involvement were treated with 2,700-3,459 MBq (mean dose, 3,120 MBq) (188)Re-HEDP. Patients underwent whole-body scans 3, 20, and 28 h after therapy. The effective half-life, residence time, and radiation-absorbed dose values were calculated for the whole body, bone marrow, kidneys, and bladder as well as for 29 bone metastases. The urinary excretion rate was determined in 6 urine samples of each patient collected over 48 h at 8-h intervals beginning immediately after the administration of (188)Re-HEDP. After injection of (188)Re-HEDP, blood samples were taken weekly for 6 wk, and platelet and leukocyte counts were performed.

RESULTS

The mean effective half-life was 15.9 +/- 3.5 h in bone metastases, 10.9 +/- 2.1 h in the bone marrow, 11.6 +/- 2.1 h in the whole body, 12.7 +/- 2.2 h in the kidneys, and 7.7 +/- 3.4 h in the bladder. The following radiation-absorbed doses were calculated: 3.83 +/- 2.01 mGy/MBq for bone metastases, 0.61 +/- 0.21 mGy/MBq for the bone marrow, 0.07 +/- 0.02 mGy/MBq for the whole body, 0.71 +/- 0.22 mGy/MBq for the kidneys, and 0.99 +/- 0.18 mGy/MBq for the bladder. (188)Re-HEDP showed a rapid urinary excretion within the first 8 h after therapy, with 41% of the (188)Re-HEDP administered being excreted. Forty-eight hours after therapy, the excretion rate was 60% +/- 12%. Only 1 patient showed a decrease of platelet count below 100 x 10(9) counts/L. None of the patients presented with a decrease of leukocyte count below 3.0 x 10(9) counts/L.

CONCLUSION

(188)Re-HEDP is an effective radiopharmaceutical used in the palliative treatment of metastatic bone pain. The radiation-absorbed dose is acceptable for bone pain palliation with low doses for the normal bone marrow and the whole body.

摘要

未标记

188铼-羟基亚乙基二膦酸盐（（188）Re-HEDP）在先前的研究中用于转移性骨痛的姑息治疗。然而，其动力学和辐射吸收剂量尚未有充分记录。因此，本研究的目的是收集（188）Re-HEDP的剂量学数据。

方法

13例有骨骼受累的前列腺癌患者接受了2700 - 3459MBq（平均剂量，3120MBq）的（188）Re-HEDP治疗。患者在治疗后3、20和28小时进行全身扫描。计算了全身、骨髓、肾脏和膀胱以及29个骨转移灶的有效半衰期、停留时间和辐射吸收剂量值。在给予（188）Re-HEDP后立即开始，每隔8小时收集每位患者的6份尿液样本，共48小时，以测定尿排泄率。注射（188）Re-HEDP后，每周采集血样共6周，并进行血小板和白细胞计数。

结果

骨转移灶的平均有效半衰期为15.9±3.5小时，骨髓为10.9±2.1小时，全身为11.6±2.1小时，肾脏为12.7±2.2小时，膀胱为7.7±3.4小时。计算得到的辐射吸收剂量如下：骨转移灶为3.83±2.01mGy/MBq，骨髓为0.61±0.21mGy/MBq，全身为0.07±0.02mGy/MBq，肾脏为0.71±0.22mGy/MBq，膀胱为0.99±0.18mGy/MBq。（188）Re-HEDP在治疗后的前8小时内尿排泄迅速，给药的（188）Re-HEDP中有41%被排泄。治疗48小时后，排泄率为60%±12%。只有1例患者血小板计数降至100×10⁹/L以下。没有患者白细胞计数降至3.0×10⁹/L以下。